Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
June 04, 2022 14:30 ET
|
Vera Therapeutics
MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremiaData presented as oral late breaker at American Transplant Congress BK Virus is a...
Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
June 02, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
May 20, 2022 16:05 ET
|
Vera Therapeutics
Atacicept is the first known investigational therapy to decrease both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies which correlate with increased risk of IgA nephropathy disease progressionNew...
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 16, 2022 07:30 ET
|
Vera Therapeutics
Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022, following positive...
Vera Therapeutics to Present at Upcoming Conferences in May 2022
May 05, 2022 16:05 ET
|
Vera Therapeutics
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus
May 03, 2022 16:33 ET
|
Vera Therapeutics
BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
May 02, 2022 19:06 ET
|
Vera Therapeutics
BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors
April 12, 2022 07:30 ET
|
Vera Therapeutics
BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 24, 2022 06:30 ET
|
Vera Therapeutics
Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim...
Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
March 21, 2022 07:30 ET
|
Vera Therapeutics
Management to provide overview of MAU868, its lead asset in the treatment of BK Virus infections in kidney transplant patients BK Virus is a leading cause of transplant loss and transplant-associated...